secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0000950170-24-105923
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences reports Q1 FY2025 cash of $4.3M, raises $1.9M in non-dilutive debt; MyoVista device on track
--------------------------------------------------------------------------------

- Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
- Subsequent to quarter end, closed $1.9M net non-dilutive 18-month loan and extended $500K loan to Sep 2025.
- FDA 510(k) submission for MyoVista wavECG device remains on track for Q1 calendar 2025.
- Cloud-based MyoVista Insights platform Phase 1 on track for end of calendar 2024; FDA submission target H2 2025.
- No revenue reported for Q1 FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017024105923/0000950170-24-105923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017024105923/hscs-20240912.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-105923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer